SERUM LEVEL OF SOME CYTOKINES IN CHILDREN 6-10 YEARS OLD WITH HIGH FREQUENCY OF ACUTE RESPIRATORY INFECTIONS
DOI:
https://doi.org/10.34287/MMT.2(53).2022.3Abstract
Objective: improved diagnosis of immune disorders in children aged 6-10 years old, who are often ill od upper respiratory tract infections (URTI), on the basis of these data, further investigation of serum equalities of cytokines, a way of diagnosing with indications in healthy children.
Materials and methods. There were 60 children of 6 to 10 years of age, from which 2 groups were formed: 1). children who are often ill with URTI (n=30); 2). children, who do not get sick often URTI (n=30).
Results. among children of 6-10 years of age, as often ill with URTI, the frequency of registration of high indications in place of interleukin-6 blood serum (by 53.3%, p<0.05), TNF (by 63.3%, p <0.05) and low indications for interleukin-10 (by 33.3%, p<0.05), it was established that there was a high probability (odds ratio) of an increase serum interleukin-6, TNF and a decrease in interleukin-10 as a reference value, it is associated with the presence of an increased incidence of URTI in children.
Conclusion. in children aged 6-10 years, as they often fall ill with URTI, may tend to intensify pro-inflammation of the immune reactions, which still does not ensure a decrease in serious illness on URTI and unsafe side of the development of opportunistic diseases.
References
Xu Z, Zhou X, Chen G. Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation. Med. Sci. Monit. 2019; 25: 984–990.
Petes C, Mariani MK, Yang Y, et al. Interleukin (IL)-6 Inhibits IL-27- and IL-30- Mediated Inflammatory Responses in Human Monocytes. Front. Immunol. 2018; 9: 256.
Belghith M, Bahrini K, Kchaou M, et al. Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease. Cytokine. 2018; 108: 160–167.
Peñaloza HF, Noguera LP, Riedel CA, Bueno SM. Expanding the current knowledge about the role of interleukin-10 to major concerning bacteria. Frontiers in microbiology. 2018; 9: 2047.
Leandro CG, Ferreira E, Silva WT, Lima-Silva AE. Covid-19 and Exercise-Induced Immunomodulation. Neuroimmunomodulation. 2020; 27 (1): 75–78.
Cuppari C, Colavita L, Miraglia Del Giudice M, et al. Recurrent respiratory infections between immunity and atopy. Pediatric Allergy and Immunology. 2020; 31: 19–21.
Freise N, Burghard A, Ortkras T, [et al.] Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation. Blood, The Journal of the American Society of Hematology, 134 (2), 134–146.
Hop HT, Reyes AWB, Huy TXN, et al. Interleukin 10 suppresses lysosomemediated killing of Brucella abortus in cultured macrophages. Journal of Biological Chemistry, 2018; 293 (9): 3134–3144.
El Hajj H, Hleihel R, El Sabban M, et al. Loss of interleukin-10 activates innate immunity to eradicate adult t-cell leukemia-initiating cells. Haematologica. 2021; 106 (5): 1443.
Yoshifuji H. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. Modern rheumatology, 2019; 29 (2): 287–293.
.Scherger S, Henao-Martínez A, Franco- Paredes C, Shapiro L. Rethinking interleukin-6 blockade for treatment of COVID-19. Medical hypotheses. 2020; 144: 110053.
